Why Coeur Mining, Inc. (CDE) Soared On Wednesday
Coeur Mining saw its share prices rise by 4.33 percent on Wednesday to finish at $8.43 apiece following the launch of a $75-million share buyback, effective through May 31, 2026.
In a statement, Coeur Mining, Inc. (NYSE:CDE) President and Chief Executive Officer Mitchell Krebs said that the initiative was aimed at boosting shareholder value.
Aerial view of a gold mine, reflecting the company's precious metals mining operations.
Coeur Mining, Inc. (NYSE:CDE) said repurchases under the program may be carried out from time to time through opportunistic open-market purchases or by other means in amounts and at prices that the company deems appropriate.
In recent news, Coeur Mining, Inc. (NYSE:CDE) said it swung to a net income of $33.4 million from a $29.1 million net loss in the same period last year. Revenues jumped by 69 percent to $360.1 million from $213.1 million year-on-year.
For the full year 2025, Coeur Mining, Inc. (NYSE:CDE) expects to produce 95,000 to 105,000 ounces of gold and 5.4 million to 6.5 million ounces of silver. It also targets to spend between $26 million and $32 million, consisting primarily of sustaining capital and underground development.
Overall, CDE ranks 7th on our list of best-performing stocks. While we acknowledge the potential of CDE, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CDE and that has 10,000x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock
Molina Healthcare, Inc. (NYSE:MOH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 28, Ryan Langston, an analyst from TD Cowen, reiterated a 'Buy' rating on the company's stock, and the associated price target was lowered to $203.00. The analyst noted that Molina Healthcare, Inc. (NYSE:MOH) continues to effectively manage the medical costs in the challenging environment, mainly in Medicaid, where it is witnessing pressures in behavioral, pharmacy, and inpatient/outpatient care. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. Molina Healthcare, Inc. (NYSE:MOH) continues to actively work with state partners in order to restore Medicaid rates to appropriate levels. It has considered increased cost trends in the Medicare and Marketplace bids for 2026. Despite challenges, Molina Healthcare, Inc. (NYSE:MOH)'s strategic efforts and adjustments in rate filings reflect growth potential, justifying the analyst's rating. For FY 2025, the Premium revenue is expected to be ~$42 billion, reflecting an increase of ~9% from FY 2024. Molina Healthcare, Inc. (NYSE:MOH) expects its FY 2025 GAAP earnings to be no less than $16.90 per diluted share. Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter. Here is what the fund said: 'Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care company. The company is the fourth largest player in managed Medicaid and has consistently delivered industry-leading margins historically. In our view, this is thanks to Molina Healthcare's exceptional management team and culture of operational excellence. Moreover, we think Molina Healthcare has a long runway for growth given its small scale relative to peers and untapped opportunities in their Medicare and Marketplace business segments. Recently, the Medicaid industry has come under substantial pressure due to a challenging redetermination cycle and additional headwinds from legislation under the current administration. This provided the opportunity to, in our view, purchase shares in a best-in-class managed care company at depressed valuation on trough earnings.' While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Earnings To Watch: Home Depot (HD) Reports Q2 Results Tomorrow
Home improvement retail giant Home Depot (NYSE:HD) will be announcing earnings results this Tuesday before the bell. Here's what to expect. Home Depot beat analysts' revenue expectations by 1.6% last quarter, reporting revenues of $39.86 billion, up 9.4% year on year. It was a slower quarter for the company, with a miss of analysts' EBITDA estimates and gross margin in line with analysts' estimates. Is Home Depot a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Home Depot's revenue to grow 4.9% year on year to $45.27 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $4.69 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Home Depot has missed Wall Street's revenue estimates twice over the last two years. Looking at Home Depot's peers in the home furnishing and improvement retail segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Floor And Decor delivered year-on-year revenue growth of 7.1%, meeting analysts' expectations, and Arhaus reported revenues up 15.7%, topping estimates by 7.4%. Floor And Decor traded up 2.2% following the results while Arhaus was also up 13.5%. Read our full analysis of Floor And Decor's results here and Arhaus's results here. There has been positive sentiment among investors in the home furnishing and improvement retail segment, with share prices up 5.8% on average over the last month. Home Depot is up 9.5% during the same time and is heading into earnings with an average analyst price target of $423.91 (compared to the current share price of $398.50). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
